Michael J. Mastrangelo

Author

Also Known As

Adam Dicker, M J Mastrangelo, M Mastrangelo, M. J. MASTRANGELO, M. J. Mastrangelo, M. J. Mastrangelo,, M. MASTRANGELO, M. Mastrangelo, M.J. Mastrangelo, MICHAEL J. MASTRANGELO

267

Publications

8.6K

Citations

H-Index

134

Concepts

All Affiliations

Thomas Jefferson University Fox Chase Cancer Center University of Kentucky Sidney Kimmel Cancer Center Wills Eye Hospital

About

Michael J. Mastrangelo is an author at Thomas Jefferson University specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	76	5.1K
2	Allergy	11	11	881
3	Health Sciences	7	7	392
4	Engineering	2	2	24
5	Education	1	1	29

Michael J. Mastrangelo

116

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Michael J. Mastrangelo, Henry Maguire, Laurence C. Eisenlohr, Cancer Gene Therapy Skin CancerMelanomaImmunologyVirologyGene Vector	1999	353
Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. David Berd, Henry Maguire, Peter A. McCue, Journal of Clinical Oncology ImmunologyPathologyVaccine TherapyImmunotherapyTumor Immunology	1990	298
Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. David Berd, Henry Maguire, Michael J. Mastrangelo PubMed ImmunologyImmunoeditingImmunotherapyAutologous Melanoma CellsAnimal Tumor Systems	1986	252
Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Rajasekharan Somasundaram, Lutz Jacob, Rolf Swoboda, PubMed Cancer ImmunosurveillanceT-regulatory CellImmunologyColorectal CancerGrowth Factor-beta	2002	182
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Masataka Ohta, Hirokazu Nagai, Makiko Shimizu, PubMed PathologyTumor BiologyOncologyMelanoma SusceptibilityCancer Cell Biology	1994	169
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. David Berd, Michael J. Mastrangelo PubMed Immune RegulationImmunologyImmunologic MechanismCd4 T Cell ResponsesImmunotherapeutics	1988	167
Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine David Berd, Takami Sato, Henry Maguire, Journal of Clinical Oncology	2003	145
Augmentation of the human immune response by cyclophosphamide. David Berd, Michael J. Mastrangelo, Paul F. Engstrom, PubMed ImmunotoxicologyImmunologyImmune RegulationPathologyImmunophenotyping	1982	138
Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials Edward F. McCiay, Michael J. Mastrangelo, David Berd, International Journal of Cancer	1992	137
Laparoscopic splenectomy: Outcomes and lessons learned from over 200 cases Adrian E. Park, Guðjón Birgisson, Michael J. Mastrangelo, Surgery LaparoscopyGynecologic SurgeryLaparoscopic SplenectomySurgeryGeneral Surgery	2000	136

Page 1